The Thrombosis & Atherosclerosis Research Institute (TaARI) is located in the David Braley Research Institute, which they share with the Population Health Research Institute (PHRI) . The core research programs at TaARI include:
- The Experimental Thrombosis and Atherosclerosis (ETA) Program, led by Jeff Weitz, which conducts fundamental research on the interplay of thrombosis and atherosclerosis with diabetes, cancer, and inflammation.
- The Clinical Thromboembolism Program (CTP), led by Sam Schulman, which performs optimal prevention, diagnosis and treatment of patients with thrombotic problems, translating current research into clinical practice.
- The Comparative Medicine Group, led by Shawn Petrik, which supports the research of an interdisciplinary group of faculty veterinarians, physicians, and basic scientists who study animal models of human disease. The research is dedicated to the enhancement of human and animal health via research, training and services.
- The Neonatal Trials Group, led by Robin Roberts, which conducts clinical trials to assess the efficacy and safety of common, but insufficiently evaluated, neonatal therapies in premature infants. The research group is co-directed by Barbara Schmidt and Haresh Kirpalani who are now at the University of Pennsylvania. Robin Roberts also provides biostatistical support to all the programs at TaARI.
“To reduce death and disability from thrombotic diseases by conducting research into the pathogenesis, prevention, diagnosis and treatment of thrombosis and vascular disease.”